Objective: The objective of this study was to investigate the factors associated with depression, including serum oxytocin (OXT) levels, disease activity, activities of daily living (ADL), and quality of life (QOL), and their effects on rheumatoid arthritis (RA). Methods: This study included 42 RA patients who received treatment with a biological agent. We measured the following variables before and after 6 months of treatment: baseline characteristics, including age, sex, disease duration, smoking, and body mass index (BMI); prednisolone and methotrexate dose; serum level of matrix metalloproteinase-3 (MMP-3); erythrocyte sedimentation rate (ESR); and C-reactive protein (CRP) level. The disease activity of RA was assessed using the Simplified Disease Activity Index (SDAI); depression was assessed using the Hamilton Depression Rating Scale (HAM-D); ADL was assessed using the Health Assessment Questionnaire; and QOL was assessed using the Short Form (SF)-36. Serum OXT levels were determined using enzyme-linked immunosorbent assay. Results: The HAM-D score significantly correlated with the SDAI, and the mental component summary (MCS) score of SF-36. However, the serum OXT levels did not correlate with the HAM-D score. Regression analysis using the HAM-D score as the objective variable identified female sex, smoking, BMI, and all the three component scores of SF-36, but not serum OXT levels, as significant factors. Comparisons between before and after treatment showed that the HAM-D score improved from 5 to 1.5; however, the serum OXT levels did not change. Conclusion: The variables of female sex, smoking, BMI, and QOL correlated with depression complicated with RA. However, serum OXT levels did not correlate directly.
Introduction
In rheumatoid arthritis (RA) patients, there are various complications. Depression is the most common complication of RA, constituting approximately 15% of all complications (1) . The odds ratio of depression in RA patients is 1.42 (95% confidence interval [CI]: 1.3, 1.5) relative to healthy people (2) . Biological agents for the treatment of RA are known to be highly effective in reducing the disease activity as well as the severity of depression as a complication of RA (3).
The level of oxytocin (OXT), also referred to as a happy hormone, is reported to be reduced in various psychiatric diseases, such as depression, bipolar disorder, schizophrenia, autism, eating disorder, developmental disorder, and social anxiety disorder (4) (5) (6) (7) (8) (9) (10) (11) (12) . There are also reports that the level of OXT is elevated by antidepressant treatment or electroconvulsive therapy (5) . In autoimmune diseases, there are reports of a mood disorder in patients with Sjogren's syndrome and fibromyalgia (13, 14) . However, there is no report of the relationship between depression and serum OXT levels in RA patients. Therefore, our aim was to investigate the relationship between serum OXT levels and depression and disease activity in RA.
Methods Participants
The study used a cross-sectional design. (15) . Variables were measured before the start of treatment and after 6 months of treatment with the biological agent. The studied variables included patient background, age, sex, disease duration, smoking history, history of use of the biological agent, body mass index (BMI), dosage of prednisolone, dosage of methotrexate (MTX), serum matrix metalloprotease-3 (MMP-3) level, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) level. The disease activity of RA was evaluated using the Simplified Disease Activity Index (SDAI); depressive status was evaluated using the Hamilton Depression Rating Scale (HAM-D); activities of daily living (ADL) were assessed using the Health Assessment Questionnaire (HAQ); and quality of life (QOL) was assessed using Short Form-36 (SF-36) (16) (17) (18) (19) (20) . SF-36 was analyzed by dividing it into three summary scores: the physical component summary (PCS), the mental component summary (MCS), and the role/social component summary (RCS). The assessment using the HAM-D was conducted under the guidance of SK.
Exclusion criteria included patients using antidepressants, pregnant women, lactating patients, and patients complicated with diseases apart from depression affecting serum OXT levels (bipolar disorder, schizophrenia, autism, eating disorders, developmental disorder, and social anxiety disorder). There were no restrictions on the use of other anti-rheumatic drugs or nonsteroidal anti-inflammatory drugs. There were no limits on age or disease duration. Patients who requested to stop the examination and patients judged as inappropriate for the study by the doctors were excluded.
Serum OXT measurements
The serum obtained at the baseline assessment was stored at normal temperature for 30 min, centrifuged at 1,500 rpm for 10 min, and then stored at -80°C until analysis. Serum OXT levels were measured using enzyme-linked immunosorbent assay (ELISA) (Catalog No. ADI-900-153A; ENZO Life Sciences, Farmingdale, NY, USA). Blood samples were collected in the morning because serum OXT levels show a diurnal variation. The solid-phase extraction of the serum samples was performed to eliminate the effects of potentially interacting molecules, as described previously (21) . Briefly, an equal volume (125 μL) of 0.1% trifluoracetic acid in water (TFA-H 2 O) was added to the serum sample (125 μL) and centrifuged at 17,000 g for 15 min at 4°C and the supernatant was collected. A C18 Sep-Pak column (200 mg; Bachem, San Carlos, CA, USA) was equilibrated with 1 mL of acetonitrile, and subsequently equilibrated 4 times with 3 mL of 0.1% TFA-H 2 O. The supernatant was applied to the C18 Sep-Pak column and washed 4 times with 3 mL of 0.1% TFA-H 2 O, and the flow-through fraction was discarded. The sample was eluted slowly by applying a 3-mL solution of 60% acetonitrile and 40% 0.1% TFA-H 2 O, followed by collection in a plastic tube. Thereafter, the solvent was evaporated using a vacuum centrifugal concentrator at 4°C and stored at -20°C until analysis.
Statistical analysis
Analysis methods were as follows: (1) correlation between HAM-D and each parameter, (2) multiple regression analysis with HAM-D as the objective variable, and (3) comparison between before and after treatment with a biological agent. All of the statistical analyses were performed using univariate and multivariate analyses in the JMP12.2 software program (SAS Institute Inc., Cary, NC, USA). We obtained written informed consent from all of the patients who enrolled in the study. The study received approval from the Bio-Ethics Committee of the Department of Medicine, Showa University School of Medicine (No. 1950).
Results
Of the 131 patients considered for the study, 42 were excluded because of primary failure, secondary failure, complications, lack of data, lack of serum samples, transfer, withdrawal from the study, and other circumstances.
Patient background data were as follows: the median patient age was 56 years (interquartile range [IQR], 42-67 years); the female:male ratio was 33:9; the SDAI was 21 (IQR, 14-29), reflecting a group of patients with moderate disease activity. The serum OXT level was 75 pg/mL (IQR, 58-90 pg/mL), and the depressed status on the HAM-D was 5 (IQR, 2.3-8; Table 1 ).
The SDAI (r=0.412) and MCS score (r=-0.555) on the SF-36 had a significant correlation with the HAM-D score. The tender joint count (TJC; r=0.391), patient's global assessment (PtGA; r=0.380), physician's global assessment (PGA; r=0.391), and HAQ score (r=0.347) had a weak correlation with the HAM-D score. However, the Table 3 ).
The comparison between before and after treatment with a biological agent showed improvement in the HAM-D score from 5 (2.25-8) before treatment to 1.5 (0.75-2.25) after treatment (p=0.000). However, the serum OXT levels were unchanged from 75 (IQR, 58-90) pg/ mL before treatment to 75 (IQR, 63-86) pg/ mL after treatment (p=0.326). Thus, no treatment-induced improvement in serum OXT levels was observed (Table 4) .
Discussion
Although the factors of depression, sex, BMI, smoking status, and QOL were correlated with RA in the study cohort, serum OXT levels were not correlated with RA in this study. The level of OXT, also known as a happy hormone, is reported to be reduced in various psychiatric diseases such as depression (4, 5). There are reports that intranasal administration of OXT improves refractory major depression (22) .
Several studies in recent years have evaluated OXT levels using ELISA from the ENZO kit. Hence, we used ELISA and radioimmunoassay (RIA) for the assessment of serum OXT levels were. In previous reports, serum OXT levels were reported to be 69.5±32.7 pg/mL in women with post-traumatic stress disorder (PTSD) associated with a traffic accident, 101.59±55.89 pg/mL in those with PTSD associated with other events, and 100±35 pg/mL in those with schizophrenia (23) (24) (25) . In children, attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) are reported to be associated with OXT levels (26) (27) (28) (29) . Depression was reported to be associated with OXT levels only based on the RIA method (5, 30, 31) . Of all the collagen diseases, fibromyalgia is the only disease for which the OXT levels have been 14, and OXT levels have not been reported in patients with RA. In healthy subjects, OXT levels were 140±133 pg/mL for elderly women and 50±38 pg/mL for elderly men (32) ( Table 5) .
In this study, we speculated that the disease activity of RA would be decreased, the depression status would be improved, and the serum OXT levels would be increased following treatment with the biological agent. However, the results showed no difference in serum OXT levels between before and after treatment.
There are several reasons that may account for this finding. The HAM-D score before the start of treatment was not high and was not stratified by the presence or absence of a depressive state. The serum OXT levels in RA patients before treatment were not low compared to those with other diseases or healthy individuals. The normal range of serum OXT levels in RA patients is unknown and did not correlate with depression that is a complication of RA. Moreover, drugs used to treat RA may affect OXT levels.
Our study had 4 limitations. First, the number of valid analysis cases was low (42 cases); thus, the small sample size may have contributed to a lack of statistical significance of the results. Second, we did not perform a radiographic evaluation of the joints, although we are aware that a radiographic evaluation is expected to influence depression. Third, no socioeconomic factors were included in our analysis. Fourth, the history of major depression was not examined.
Rheumatoid arthritis complicated with depression may be related to the following variables: female sex, a history of smoking, low BMI, and poor QOL. However, serum OXT levels may not be directly related to RA complicated with depression. Informed Consent: Written informed consent was obtained from patients who participated in this study. 
